Our Latest Reports
NEW REPORT • January 2024
Available Reports
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
New BIO Industry Analysis trend data have been released for Emerging Therapeutic Company Investment, R&D-Stage Out-licensing, and Acquisitions.
BIO’s Industry Analysis Team presents FDA Approval Trends that are filterable by various attributes including: size of company, molecule size, disease area, and various expedited approval pathways.
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
Highly Prevalent Chronic Disease Series
Clinical Success Rates
Explore BIO
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved